A recent poll indicated that 15.5 million Americans use injectable weight loss drugs such as Ozempic and Wegovy, but many relied on cheaper compounded versions that are now disappearing. These compounded GLP-1s helped individuals afford similar medications for obesity management when brand names often cost around $1,000 monthly without insurance. The FDA initiated a shortage of key diabetes medications like semaglutide, allowing compounding pharmacies to create affordable alternatives that improved financial access. The upcoming loss of these compounded drugs raises concerns about the future of weight management for many individuals.
"Compounding usually improves access from a drug shortage perspective, and then also the accessibility from the expense. A lot of these drugs aren't covered by insurance." - Dr. Michael Ganio
"The route of administration, the concentration, the dosage form is identical to a commercially available product," says Dr. Michael Ganio.
Collection
[
|
...
]